Alacris Theranostics and Max Planck Institute for Molecular Genetics collaborate in TREGeneration Consortium

Berlin, 27th February 2015 – The teams led by Marie-Laure Yaspo at the Max Planck Institute for Molecular Genetics and by Hans Lehrach at Alacris Theranostics GmbH in Berlin are partners in a European consortium that recently obtained funding from the European Commission under the Horizon 2020 program to participate in a clinical research project for the treatment of Graft versus Host Disease, a serious complication following bone marrow transplantation. A total of 6 million euros was awarded to the consortium to perform a 5-year research project comprising a set of five parallel clinical trials.

Transplantation of stem cells can save the life of patients suffering from leukemia or other blood diseases. Between 30 and 50% of patients undergoing stem cell transplantation suffer from Graft versus Host Disease, a potentially serious condition that results from donor immune cells “attacking” patient tissues like skin, internal organs and mucosa. The TREGeneration project aims to test a cell-based therapeutic approach, expected to result in fewer side effects than the pharmacological strategies currently available.

Find the full press release here: